Broad mucosal vaccine to protect against norovirus
Development of novel multivalent mucosal vaccines for human noroviruses
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11325782
A live viral vaccine built on safe, approved vaccine platforms to help children and others develop strong gut and whole-body protection against common norovirus strains.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11325782 on ClinicalTrials.gov |
What this research studies
This project adapts two approved vaccine platforms (the rotavirus vaccine RotaTeq and the measles/mumps/rubella vaccine) to carry key norovirus proteins so the immune system can recognize the virus. Scientists will insert parts of the norovirus capsid gene (VP1 and the P domain) from several common genotypes into multiple vaccine strains to create a multivalent formulation. The goal is to trigger both mucosal (gut) and systemic immune responses that protect against many norovirus types. Early testing will use cell culture systems and animal models to evaluate immune responses and safety before any human trials.
Who could benefit from this research
Good fit: Future clinical testing would likely focus on infants and young children (including ages 0–11) who are at high risk for norovirus infection.
Not a fit: People with severe immune system problems or known allergies to vaccine components may not be able to receive or benefit from live-vectored vaccines.
Why it matters
Potential benefit: If successful, this could produce a broadly protective, long-lasting vaccine that reduces norovirus-caused vomiting and diarrhea, especially in young children.
How similar studies have performed: Live attenuated vaccines like RotaTeq and MMR have a long record of safety and strong protection, but no licensed norovirus vaccine exists yet and this multivalent live-vectored approach remains early-stage.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, JIANRONG — OHIO STATE UNIVERSITY
- Study coordinator: LI, JIANRONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.